Send us Fan Mail
In this episode, Rachael interviews a world renowned physician and clinical trialist, open to sharing details about what's happening behind the scenes in the diabetes research world when it comes to new therapies for T1D, but at a global level.
Her guest? Leading scientist and pediatric endocrinologist from the University of Florida, Dr. Michael Haller. He answers questions about IV infusions of Teplizumab and various forms of anti-thymocyte globulin (ATG). They talk about a clinical trial called "Safeguard", which has been fast-tracked by the FDA, aiming to study a different human version of anti-thymocyte globulin (ATG).
Dr. Haller also opens up on details surrounding events that occurred during the American Diabetes Association (ADA) Annual Scientific Sessions in June 2026, in New Orleans, Louisiana. The story actually went VIRAL in the press; even making it to the front page of the New York Times. This was after several very prominent scientists were escorted out of the conference for distributing peer-reviewed published journal articles. Since that time, a formal boycott on the ADA has been called, asking for an internal review of the events that occurred. Now, over 1000 physicians and scientific leaders have signed the boycott, yet nothing has changed. So the diabetes community continues to search for answers.
Rachael asks Dr. Haller, "What exactly happened since you were there?" And if this boycott is honored, "Will it improve the lives of people living with diabetes?" This is the FIRST time any physician has freely spoken on camera about what actually happened, so it's an episode you WON'T want to miss.
https://youtube.com/@thediabetescollective?si=6gvVGtd5Um9XSb4u
https://www.instagram.com/thediabetescollective?igsh=bGI5bno2NnUwNmp3&utm_source=q
https://www.facebook.com/share/14mrAd3kbVj/?mibextid=wwXIfr
https://www.tiktok.com/@thediabetescollective?_r=1&_t=ZT-97f3bZc8GU9